Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer

Molecular Biology Reports

Volumn 39, Issue 1, 2012, Pages 335-341

  Tepeli, Emre ^a   Caner, Vildan ^a   Büyükpınarbaşılı, Nur ^b   Çetin, G Ozan ^a   Düzcan, Füsun ^a   Elmas, Levent ^a   Bağcı, Gülseren ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b Yedikule Teaching Hospital   (Turkey)

Author keywords

ERCC1; IHC; Non small cell lung cancer; Real time quantitative PCR

Indexed keywords

DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA;

AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; EXCISION REPAIR CROSS COMPLEMENTING GROUP 1 GENE; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VALIDATION PROCESS;

EID: 84855192513     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0743-0     Document Type: Article

References (33)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer Statistics, 2008 CA Cancer J Clin 58 2 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
2. Ministry of Health Republic of Turkey (2009) Cancer statistics in Turkey. http://www.kanser.gov.tr. Accessed Dec 2010
3. GR Simon A Sharma A Cantor P Smith G Bepler 2005 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Chest 127 3 978 983 15764785 10.1378/chest.127.3.978 (Pubitemid 40775532)
4. RV Lord J Brabender D Gandara, et al. 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2286 2291 12114432 1:CAS:528:DC%2BD38XmtVWhsLw%3D (Pubitemid 34753602)
5. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 10 983 991 16957145 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
6. T Fujii S Toyooka K Ichimura, et al. 2008 ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer Lung Cancer 59 3 377 384 17905465 10.1016/j.lungcan.2007.08.025 (Pubitemid 351335101)
7. IU De Silva PJ McHugh PH Clingen JA Hartley 2000 Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells Mol Cell Biol 20 7980 7990 11027268 10.1128/MCB.20.21.7980-7990.2000
8. E Reed 1998 Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy Cancer Treat Rev 24 331 344 9861196 10.1016/S0305-7372(98)90056-1 1:CAS:528:DyaK1MXitVCqtg%3D%3D (Pubitemid 28537769)
9. LJ Niedernhofer H Odijk M Budzowska, et al. 2004 The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks Mol Cell Biol 24 13 5776 5787 15199134 10.1128/MCB.24.13.5776-5787.2004 1:CAS:528:DC%2BD2cXls1aqtro%3D (Pubitemid 38787963)
10. J Li ZN Li YJ Du XQ Li QL Bao P Chen 2009 Expression of MRP1, BCRP, LRP, and ERCC1in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival Clin Lung Cancer 10 6 414 421 19900859 10.3816/CLC.2009.n.078 1:CAS:528:DC%2BD1MXhsFahsbbN
11. S Scheil-Bertram P Tylus-Schaaf A du Bois P Harter M Oppitz N Ewald-Riegler A Fisseler-Eckhoff 2010 Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma Gynecol Oncol 119 2 325 331 20728204 10.1016/j.ygyno.2010.07.018 1:CAS:528:DC%2BC3cXht1KqsrfI
12. P Ceppi M Papotti G Scagliotti 2010 New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS Adv Med Sci 55 1 22 25 20494871 10.2478/v10039-010-0017-4 1:CAS:528:DC%2BC3cXhtFWgu73P
13. A Vilmar E Santoni-Rugiu JB Sørensen 2010 ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial Eur J Cancer 46 1554 1562 20395129 10.1016/j.ejca.2010.02.045 1:CAS:528:DC%2BC3cXmslers74%3D
14. M Cobo D Isla B Massuti, et al. 2007 Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 19 2747 2754 17602080 10.1200/JCO.2006.09.7915 1:CAS:528:DC%2BD2sXosValtLk%3D (Pubitemid 47123183)
15. KA Olaussen G Mountzios JC Soria 2007 ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer Curr Opin Pulm Med 13 4 284 289 17534174 10.1097/MCP.0b013e32816b5c63 1:CAS:528:DC%2BD2sXosVajur0%3D (Pubitemid 46847293)
16. S Ren S Zhou L Zhang, et al. 2010 High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients Cancer Invest 28 10 1078 1083 20504223 10.3109/07357901003735659 1:CAS:528:DC%2BC3cXhsVeksbjN
17. R Booton T Ward L Ashcroft J Morris J Heighway N Thatcher 2007 ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer J Thorac Oncol 2 10 902 906 17909351 10.1097/JTO.0b013e318155a637 (Pubitemid 47511592)
18. Travis WD, Brambilla E, Müller-Hermelink HK, Haris CC (2004) Tumours of the lung. In: World Health Organization classification of tumours: pathology & genetics-tumours of lung, pleura, thymus, and heart. IARC Press, Lyon, pp 10-11
19. KH Lee HS Min SW Han, et al. 2008 ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer Lung Cancer 60 3 401 407 18036700 10.1016/j.lungcan.2007.10.014 (Pubitemid 351726353)
20. P Ceppi M Volante S Novello, et al. 2006 ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann Oncol 17 12 1818 1825 16980606 10.1093/annonc/mdl300 1:STN:280:DC%2BD28jhtlWhug%3D%3D (Pubitemid 44884058)
21. T Takenaka T Yano C Kiyohara, et al. 2009 Effects of excision repair cross-complementation group 1 (ERCC1) single nücleotide polymorphisms on the prognosis of non-small cell lung cancer patients Lung Cancer 67 1 101 107 10.1016/j.lungcan.2009.03.007
22. S Smith D Su IA Longrais, et al. 2007 ERCC1 genotype and phenotype in epithelial ovarian cancer Identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J Clin Oncol 25 5172 5179 18024864 10.1200/JCO.2007.11.8547 1:CAS:528:DC%2BD2sXhsVKnsb%2FF (Pubitemid 350232247)
23. L Wang JA Aakre R Jiang, et al. 2010 Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA J Thorac Oncol 5 6 778 785 20421821 10.1097/JTO.0b013e3181d6e0b3
24. K Azuma Y Komohara T Sasada, et al. 2007 Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy Cancer Sci 98 9 1336 1343 17640298 10.1111/j.1349-7006.2007.00557.x 1:CAS:528:DC%2BD2sXhtVaksr3F (Pubitemid 47241754)
25. JJ Yu C Mu KB Lee 2006 A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues Mutat Res 382 13 20
26. W Zhou G Liu S Park, et al. 2005 Gene smoking Interaction associations for the ERCC1 polymorphisms in the risk of lung cancer Cancer Epidemiol Biomarkers Prev 14 491 496 15734977 10.1158/1055-9965.EPI-04-0612 1:CAS:528:DC%2BD2MXhs1GhsLY%3D (Pubitemid 40270116)
27. RA Britten D Liu A Tessier MJ Hutchison D Murray 2000 ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells Int J Cancer 89 5 453 457 11008208 10.1002/1097-0215(20000920)89:5<453::AID- IJC9>3.0.CO;2-E 1:CAS:528:DC%2BD3cXnsFWms74%3D
28. Z Zheng T Chen X Li E Haura A Sharma G Bepler 2007 DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl J Med 356 8 800 808 17314339 10.1056/NEJMoa065411 1:CAS:528:DC%2BD2sXhvFKltLs%3D (Pubitemid 46294612)
29. G Simon A Sharma X Li 2007 Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer J Clin Oncol 25 19 2741 2746 17602079 10.1200/JCO.2006.08.2099 1:CAS:528:DC%2BD2sXosValtLg%3D (Pubitemid 47123182)
30. IY Chang MH Kim HB Kim DY Lee SH Kim HY Kim HJ You 2005 Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin Biochem Biophys Res Commun 327 1 225 233 15629453 10.1016/j.bbrc.2004. 12.008 1:CAS:528:DC%2BD2MXksFGn (Pubitemid 40051375)
31. L Lan T Hayashi RM Rabeya, et al. 2004 Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells DNA Repair 3 2 135 143 14706347 10.1016/j.dnarep.2003.10.005 1:CAS:528:DC%2BD3sXhtVWjt77F (Pubitemid 38045244)
32. LJ Niedernhofer N Bhagwat RD Wood 2007 ERCC1 and non-small-cell lung cancer N Engl J Med 356 24 2538 2540 17568038 10.1056/NEJMc070742 1:CAS:528:DC%2BD2sXms1Siurg%3D
33. E Reed 2005 ERCC1 and clinical resistance to platinum-based therapy Clin Cancer Res 11 17 6100 6102 16144907 10.1158/1078-0432.CCR-05-1083 1:CAS:528:DC%2BD2MXpslansrw%3D (Pubitemid 41262934)